✦ LIBER ✦

1031 DURABILITY OF PEGINTERFERON ALFA-2B TREATMENT BEYOND 5 YEARS IN PATIENTS WITH HEPATITIS B E ANTIGEN (HBEAG) POSITIVE CHRONIC HEPATITIS B

✍ Scribed by Wong, V.W.-S.; Wong, G.L.-H.; Yan, K.K.-L.; Chim, A.M.-L.; Chan, H.-Y.; Chan, H.L.-Y.

Book ID: 121976183
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 49 KB
Volume: 52
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(10)61032-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Durability of peginterferon alfa-2b trea

Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

✍ Vincent Wai-Sun Wong; Grace Lai-Hung Wong; Kenneth Kar-Lung Yan; Angel Mei-Ling 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 256 KB 👁 2 views

Hepatitis B e antigen as a predictor for

Hepatitis B e antigen as a predictor for hepatitis B e antigen–positive chronic hepatitis B patients with peginterferon alfa-2a therapy

✍ En-Qiang Chen; Hong Tang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 2 views

PROVE1 trial, 1 in which in the group with an identical treatment schedule, the percentage of patients obtaining SVR with respect to RVR was 75% only. In other words, RVR seems easier to obtain with telaprevir, but less frequently predicts a favorable treatment outcome. A possible explanation might

Factors That Predict Response of Patient

Factors That Predict Response of Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B to Peginterferon-Alfa

✍ Erik H.C.J. Buster; Bettina E. Hansen; George K.K. Lau; Teerha Piratvisuth; Stef 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 1003 KB

Prediction of sustained response to pegi

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

✍ Milan J. Sonneveld; Vincent Rijckborst; Charles A. B. Boucher; Bettina E. Hansen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 1 views

Serum hepatitis B surface antigen (HBsAg) levels may reflect the immunomodulatory efficacy of pegylated interferon (PEG-IFN). We investigated within a large randomized trial whether quantitative HBsAg levels predict response to PEG-IFN in patients with hepatitis B e antigen (HBeAg)-positive chronic

Hepatitis B surface antigen: association

Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients

✍ Teerha Piratvisuth, Patrick Marcellin, Matei Popescu… 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 399 KB

Entecavir treatment for up to 5 years in

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B

✍ Ting-Tsung Chang; Ching-Lung Lai; Seung Kew Yoon; Samuel S. Lee; Henrique Sergio 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 371 KB 👁 2 views

Sustained virologic suppression is a primary goal of therapy for chronic hepatitis B (CHB). In study entecavir (ETV)-022, 48 weeks of entecavir 0.5 mg was superior to lamivudine for virologic suppression for hepatitis B e antigen (HBeAg)-positive CHB. A total of 183 entecavir-treated patients from E